Floatz logo

Monomethyl Fumarate

Recurrent Rhabdomyosarcoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
Children's National Research Institute
Phase 2BB
Fludarabine
M.D. Anderson Cancer Center
Phase 2CCC
CYCLOSPORIN A
M.D. Anderson Cancer Center
Phase 2CCC
5-azacytidine
National Cancer Institute (NCI)
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC

View all 15 →

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →